🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Breast Cancer (Locally Advanced or Metastatic)

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites📍 Freiburg im Breisgau📍 Paderborn📍 Ravensburg iOMEDICO AG · Tests: Elacestrant, Standard of care (Investigator Choice) Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06609187Phase 11 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: GNC-077 FDG PET-CT in Advanced Breast Cancer NCT07173868n/a1 site📍 Seoul Samsung Medical Center Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer NCT05430399Phase 32 sites📍 Guangzhou📍 Hunan Sun Yat-sen University · Tests: utidelone, docetaxel A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer NCT03424005Phase 1, Phase 255 sites📍 Duarte📍 Duarte📍 Irvine Hoffmann-La Roche · Tests: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites📍 Xiamen📍 Lanzhou📍 Shijiazhuang Hoffmann-La Roche · Tests: Inavolisib, Palbociclib, Fulvestrant A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Avapritinib Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) NCT05660083Phase 23 sites📍 Bethesda📍 Houston📍 Houston The Methodist Hospital Research Institute · Tests: L-NMMA A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites📍 Huntsville📍 Tucson📍 Duarte Genentech, Inc. · Tests: GDC-4198, Giredestrant, Abemaciclib Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer NCT06434064Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site📍 Shanghai Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer NCT07658183Phase 21 site📍 Shanghai Shanghai Best-Link Bioscience, LLC · Tests: BL0175 Injection, BL0175 Injection A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors NCT06503783Phase 12 sites📍 Harbin📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M17D1 A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites📍 Bengbu📍 Hefei📍 Hefei Genor Biopharma Co., Ltd. · Tests: GB491 combined with Letrozole, Placebo combined with Letrozole A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Miami Astellas Pharma Global Development, Inc. · Tests: ASP546C A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients NCT03671044Phase 34 sites📍 Columbus📍 Springfield📍 Canton Jina Pharmaceuticals Inc. · Tests: Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2) Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor NCT05523947Phase 1, Phase 219 sites📍 Boston📍 Nashville📍 Adelaide Yuhan Corporation · Tests: YH32367 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients NCT06690840Phase 25 sites📍 Monza📍 Roma📍 Roma European Institute of Oncology · Tests: Atezolizumab in combination with Cyclophosphamide and Vinorelbine A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 SMP-656 for HER2-Positive Advanced Breast Cancer NCT07726342Phase 215 sites📍 Hefei📍 Beijing📍 Beijing Chengdu SciMount Pharmatech Co., Ltd. · Tests: SMP-656 Injection, SMP-656 Injection A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC NCT06439771Phase 21 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202 should be intravenously infused Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer NCT06942234Phase 1, Phase 21 site📍 Shanghai Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Tests: JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin, Pembrolizumab A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors NCT06827613Phase 1, Phase 28 sites📍 Los Angeles📍 Los Angeles📍 Boston Marengo Therapeutics, Inc. · Tests: STAR0602, Sacituzumab Govitecan (SG) Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy